WO1999007826A1 - Novel lactic acid bacteria - Google Patents

Novel lactic acid bacteria Download PDF

Info

Publication number
WO1999007826A1
WO1999007826A1 PCT/KR1998/000191 KR9800191W WO9907826A1 WO 1999007826 A1 WO1999007826 A1 WO 1999007826A1 KR 9800191 W KR9800191 W KR 9800191W WO 9907826 A1 WO9907826 A1 WO 9907826A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactic acid
bacteria
acid bacteria
dental plaque
inhibit
Prior art date
Application number
PCT/KR1998/000191
Other languages
English (en)
French (fr)
Inventor
Jong Suk Oh
Original Assignee
Jong Suk Oh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019970037819A external-priority patent/KR19990024297A/ko
Priority claimed from KR1019980019512A external-priority patent/KR19990086509A/ko
Application filed by Jong Suk Oh filed Critical Jong Suk Oh
Priority to CA002299627A priority Critical patent/CA2299627A1/en
Priority to IL13441098A priority patent/IL134410A0/xx
Priority to JP2000506311A priority patent/JP2001512670A/ja
Priority to EP98931104A priority patent/EP1002052A1/en
Priority to BR9814737-4A priority patent/BR9814737A/pt
Priority to AU81312/98A priority patent/AU752706B2/en
Priority to MXPA00001347 priority patent/MXPA00001347A/es
Publication of WO1999007826A1 publication Critical patent/WO1999007826A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/36Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G9/363Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C15/00Butter; Butter preparations; Making thereof
    • A23C15/12Butter preparations
    • A23C15/123Addition of microorganisms or cultured milk products; Addition of enzymes; Addition of starter cultures other than destillates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00Cheese; Cheese preparations; Making thereof
    • A23C19/06Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061Addition of, or treatment with, microorganisms
    • A23C19/062Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1236Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056Spread compositions
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/36Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G9/366Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46Streptococcus ; Enterococcus; Lactococcus

Definitions

  • the present invention relates to some novel lactic acid bacteria which inhibit the production of dental plaque in human mouths. More specifically, the production of water- insoluble glucan (mutan) , a major component of dental plaque, which is produced by bacteria normally inhibiting in human mouths, can be inhibited by the novel bacteria. Oral anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis (malodor) can be inhibited by the novel bacteria, too. These lactic acid bacteria belong to Enterococcus spp., Lactobacillus spp., Lactococcus spp., and Stretococcus spp.
  • Lactic acid bacteria generally ferment carbohydrates to lactic acid. Lactic acid bacteria live in the oral cavities and the alimentary tracts of men and animals and are utilized for the manufacture of fermentative foods, such as yogurt, cheese, etc. In addition, they are used for the production of biologically active materials, such as medicines. Representatives of these lactic acid-producing bacteria are Streptococcus thermophilus, Enterococcus faecalis, Enterococcus durans, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, and Lactobacillus plantarum. As inhabitants in the entrails of men and animals, these Gram- positive lactic acid bacteria are known to play an important role in maintaining the entrails healthy by the production of lactic acid and antibacterial materials which inhibit the growth of pathogenic bacteria.
  • Glucan is either water-soluble glucan, dextran having 1,6- linkage as a predominant linkage, or water- insoluble glucan (mutan) having 1,3- ⁇ linkage as a predominant linkage.
  • water-insoluble glucan (mutan) serves as a main matrix of dental plaque.
  • Dextranase ⁇ -1,6 glucan hydrolase which digests dextran, was tested as to its ability to prevent dental plaque.
  • European patent publication number 0-524-732- A2 disclosed the use of Streptococcus salivarius which was capable of extracellular production of dextranase. But its effect on preventing dental plaque is questionable because dextranase can not digest mutan, the main matrix of dental plaque. Streptococcus salivarius is not used as the starter bacteria fermenting milk.
  • Glucan is either water-soluble or water-insoluble (mutan) , each being synthesized from sucrose by the glucosyltransferase secreted from Streptococcus mutans, the most important bacteria among dental plaque-forming bacteria. However, only the water-insoluble glucan, mutan, is the main matrix of dental plaque.
  • Enterococcus spp. 1357 Lactobacillus spp. V20, and H 2 0 2 -producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis (Bergey's Manual of Systematic Bacteriology vol. 2: Williams & Wilkins, Baltimore, London, Los Angeles, Sydney, 1986) have a growth-inhibitory activity on Streptococcus mutans. When Streptococcus mutans was cultured with Enterococcus spp. 1357, Lactobacillus spp.
  • Streptococcus oralis (ATCC 35037) as a representative of H 2 0 2 -producing Streptococci in the broth
  • the colony-forming number of Streptococcus mutans was decreased to about one hundredth compared with that of Streptococcus mutans alone.
  • the production of water-insoluble glucan or dental plaque was also suppressed significantly due to inhibition of Streptococcus mutans.
  • dental plaque adherent to the surface of teeth, provides a suitable habitat at which Streptococcus mutans as well as other bacteria proliferate and causes the dental caries formed, and it was an object of the present study to find novel bacteria which could inhibit the production of water-insoluble glucan or dental plaque by Streptococcus mutans in the mouth.
  • Anaerobic bacteria occur in high proportions in periodontitis as well as gingivitis of oral cavities. The proportions of anaerobic bacteria increase significantly (above 90% of microflora in periodontitis lesion) with increasing severity of the diseases.
  • Predominant anaerobic bacteria causing gingivitis are Prevotella intermedia and Fusobacterium nucleatum.
  • Predominant anaerobic bacteria causing periodontitis include Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Prevotella intermedia, and Fusobacterium nucleatum (Contemporary Oral Microbiology and Immunology, Mosby-Year Book, St. Louis, 1992). These anaerobic bacteria produce malodorous components such as volatile sulfur compounds in mouth. The predominant volatile sulfur compounds are hydrogen sulfide from L- cysteine and methyl mercaptan from L-methionine (Persson, S., Oral Microbiol Immunol, 7:378, 1992). Lactobacillus spp.
  • V20 and H 2 0 2 -producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis produce hydrogen peroxide inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, so improving and preventing the lesions, and decreasing the accompanied halitosis.
  • the hydrogen peroxide is an oxidizing agent inactivating enzymes by converting functional -SH groups to the oxidized S-S form and is used as a disinfectant against bacteria, especially anaerobics. Another object of this research was to provide foods or beverages employing the lactic acid bacteria.
  • the lactic acid bacteria When the foods containing the lactic acid bacteria capable of directly inhibiting the production of water-insoluble glucan or having the growth-inhibitory activity on the microorganisms which contribute to the formation of dental plaque are eaten, the lactic acid bacteria naturally suppress the formation of dental plaque and consequently prevent dental caries formation. And when the foods contain the lactic acid bacteria capable of inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, the lactic acid bacteria naturally improve and prevent gingivititis, periodontitis, and accompanied halitosis.
  • Lactic acid bacteria were taken from human bodies, streaked on Brain Heart Infusion agar, and cultured at 37°C. Thereafter, separated bacterial colonies were tested whether they could suppress the production of the water-insoluble glucan that Streptococcus mutans (Ingbritt strain) produced.
  • Streptococcus mutans Ingbritt strain
  • 3 mL of a Brain Heart Infusion medium supplemented with 0.5% yeast extract and 5% sucrose was inoculated with 0.1 mL of Streptococcus mutans and 0.1 L of a culture broth of the separated bacteria.
  • Streptococcus mutans was inoculated alone in a Brain Heart Infusion medium containing yeast extract and sucrose.
  • the cuvette was placed at an angle of 30° to the horizontal plane of an incubator and incubated for 1 day at 37 °C, in order for the Streptococcus mutans to produce water- insoluble glucan. After removing the culture broth, the cuvette was washed with 4 mL of distilled water and then, filled with 3 mL of distilled water. Its absorbance (OD) at 550 nm was measured by a spectrophotometer . Because the OD value was proportional to the water-insoluble glucan produced, the bacteria which brought about a significantly lower OD value compared with the control, were isolated as dental plaque-inhibitory strains.
  • the isolated strains were streaked on the Brain Heart Infusion agar containing 0.25mg/mL 3, 3', 5,5'- tetramethylbenzidine dihydrochloride and O.Olmg/mL horseradish peroxidase and incubated in anaerobic incubator for 48 hours. Lactobacillus spp. V20 formed the blue colonies, indicating that Lactobacillus spp. V20 had the capability to produce hydrogen peroxide.
  • microbiological properties of the isolated strains such as morphological and physiological properties (Table 1) , and sugar catabolytic ability (Table 1) were investigated.
  • novel lactic acid bacteria being able to inhibit the production of dental plaque were isolated and assayed in comparison with the control in vitro. Further, the novel properties were tested in vivo, that is, the isolated novel bacteria were applied to the human oral cavity.
  • M17 medium An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5% yeast extract, 5% sucrose and 0.1M TES (pH 8.0). Three milliliters of the constituted medium were transferred to a disposable cuvette which was, then, inoculated with 75 ⁇ l of Streptococcus mutans overnight culture. The cuvette was placed at an angle of 30° to the horizontal plane in an incubator and cultured at 30°C for 1 day. The content was removed and then, the cuvette was washed with 3mL of distilled water. Thereafter, the cuvette was filled with 4mL of distilled water and the absorbency at 550nm was measured by a spectrophotometer . This measurement was repeated three times and the average value was obtained (Table 3) . TABLE 3 Inhibitory Effect of Lactic Acid Bacteria on the Production of Water-Insoluble Glucan
  • M17 medium An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5% yeast extract, 5% sucrose,- and 0.1M TES (pH 8.0).
  • MRS medium An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5% yeast extract, 5% sucrose,- and 0.1M TES (pH 8.0).
  • One hundred and fifty milliliters of the constituted medium were poured into beaker.
  • 0.016 inch stainless steel orthodontic wires (45mg) were immersed in the medium.
  • Streptococcus mutans was inoculated at the concentration of 2.5X10 6 per mL of the medium. Thereafter, the lactic acid bacterial strains were inoculated in the medium at the concentration of 5 times higher than that of Streptococcus mutans and incubated in a C0 2 incubator at 37°C for 6.5 hours with shaking.
  • Fig. 1(A) is a photograph of the culture of Streptococcus mutans alone while Fig. 1(B) is that of the co-culture of Streptococcus mutans and Lactococcus spp. 1370.
  • Plaque scores were performed by Quigley and Hein Plaque Index after disclosing all plaque except third molars.
  • the volunteers were randomly assigned to two groups (each nineteen persons), group I mouthrinsing with Lactococcus spp. 1370 while group II mouthrinsing with Lactobacillus spp. V20.
  • Test bacterial suspensions were prepared by incubating either Lactococcus spp. 1370 or Lactobacillus spp. V20 in milk for 24 hours. Volunteers rinsed immediately once after oral prophylaxis and twice after meals with 20 mL of
  • Lactobacillus spp. V20 was cultured in MRS media for 24 hours.
  • Prophyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum were cultured in the anaerobic bacteria culture broth containing Brain Heart Infusion media 18.5 g, yeast extract 5.0 g, hemin solution 10 mL (dissolved 50 mg hemin in 1 N sodium hydroxy solution 1 mL and added with distilled water 100 L) , and vitamin K solution 0.2 mL (vitamin K solution 0.15 mL mixed with 95% ethanol 30 mL) per liter in anaerobic incubator for 36 hours.
  • Actinobacillus actinomycetemcomitans was cultured in the TSBV media containing Tryptic soy broth 30 g, yeast extract 1.0 g, horse serum 100 mL, bacitracin 75 mg, and vancomycin 5 mg per liter in anaerobic incubator for 36 hours.
  • Culture suspension 0.1 mL of Lactobacillus spp. V20 and each anaerobic bacterium at the concentration of 1.4X10 8 per mL were inoculated singly or in combination in the media containing anaerobic bacteria culture broth or TSBV media 3.7 mL mixed with MRS broth 0.3 mL, and cultured in anaerobic incubator for 36 hours.
  • the culture suspension was diluted and inoculated on MRS agar, anaerobic bacteria culture agar containing 3% sheep blood or TSBV agar. At 72 hours after culturing, the number of colonies was counted.
  • the colony-forming units of Lactobacillus spp. V20 and each anaerobic bacterium were increased after being cultured singly, whereas the colony of each anaerobic bacterium was not found after being cultured in combination with Lactobacillus spp. V20.
  • the colony-forming units were not decreased significantly (Table 5) .
  • Streptococcus oralis (ATCC 35037) as a representative of H 2 0 2 -producing Streptococci was cultured with each anaerobic bacterium by the above mentioned method, anaerobic bacteria did not form a colony on the media.
  • a broth culture containing the novel lactic acid bacterial strains was added at an amount of 0.1 vol. percent to the food just before fermentation and subjected to fermentation along with the existing bacteria to produce yogurt foods.
  • the resulting yogurt foods were tasted by 10 panelists. They noted no different flavor between the test samples and the commercially available foods (controls) .
  • the lactic acid bacterial strains were added at an amount of 0.2 vol. percent. A response that these test samples thus obtained were not different from the control foods in taste was drawn from 10 panelists who took part in the tasting tests.
  • butter foods which were manufactured by a typical procedure were added with 0.2 wt. percent of the freeze-dried lactic acid bacterial strains. These butter foods thus obtained were given as taste samples .
  • novel lactic acid bacteria were cultured and freeze-dried (lyophilized) . These freeze-dried bacteria in capsule, tablet, and small package could be taken singly or with other bacteria or materials. These freeze-dried products thus obtained were given taste samples.
  • the lactic acid bacterial strains were applied for various foods, including gum, shortening, ice cream, margarine, kimchi, etc.
  • novel lactic acid strains have a potent and lasting inhibitory effect on the production of water-insoluble glucan or dental plaque in human mouth, or on the growth of anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis .
  • novel strains were found to be able to be applied for various foods as well as directly to the teeth.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Edible Oils And Fats (AREA)
PCT/KR1998/000191 1997-08-07 1998-07-02 Novel lactic acid bacteria WO1999007826A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002299627A CA2299627A1 (en) 1997-08-07 1998-07-02 Novel lactic acid bacteria
IL13441098A IL134410A0 (en) 1997-08-07 1998-07-02 Novel lactic acid bacteria
JP2000506311A JP2001512670A (ja) 1997-08-07 1998-07-02 新規な乳酸菌
EP98931104A EP1002052A1 (en) 1997-08-07 1998-07-02 Novel lactic acid bacteria
BR9814737-4A BR9814737A (pt) 1997-08-07 1998-07-02 Bactérias produtoras de ácido lático
AU81312/98A AU752706B2 (en) 1997-08-07 1998-07-02 Novel lactic acid bacteria
MXPA00001347 MXPA00001347A (es) 1997-08-07 1998-07-02 Bacterias de acido lactico novedo

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR1019970037819A KR19990024297A (ko) 1997-08-07 1997-08-07 인체 구강내 치태형성을 억제하는 신규한 유산균
KR1997/37819 1997-08-07
KR19980000213A KR100266752B1 (ko) 1997-08-07 1998-01-07 인체 구강내 치태형성을 억제하는 신규한 유산균
KR1998/213 1998-01-07
KR1998/19512 1998-05-28
KR1019980019512A KR19990086509A (ko) 1998-05-28 1998-05-28 인체 구강내 혐기성 세균을 억제하는 유산균

Publications (1)

Publication Number Publication Date
WO1999007826A1 true WO1999007826A1 (en) 1999-02-18

Family

ID=27349588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1998/000191 WO1999007826A1 (en) 1997-08-07 1998-07-02 Novel lactic acid bacteria

Country Status (11)

Country Link
EP (1) EP1002052A1 (tr)
JP (1) JP2001512670A (tr)
KR (1) KR100266752B1 (tr)
CN (1) CN1268172A (tr)
AU (1) AU752706B2 (tr)
BR (1) BR9814737A (tr)
CA (1) CA2299627A1 (tr)
IL (1) IL134410A0 (tr)
MX (1) MXPA00001347A (tr)
TR (1) TR200000360T2 (tr)
WO (1) WO1999007826A1 (tr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173555A1 (en) * 1999-04-26 2002-01-23 Innoscent Ltd. Method and kit for indicating the level of bad breath
WO2002080946A1 (en) * 2001-04-02 2002-10-17 Wakamoto Pharmaceutical Co.,Ltd. Compositions for preventing and/or treating oral diseases
JP2003502375A (ja) * 1999-06-21 2003-01-21 ブイエスエル・ファーマ・リミテッド 乳酸菌の配合物並びに感染症および炎症の予防および/または処置のためのその使用
WO2003014029A3 (en) * 2001-08-06 2004-03-18 A Y Lab Ltd Control of development of biofilms in industrial process water
CN102352324A (zh) * 2003-01-29 2012-02-15 生命大地女神有限公司 乳酸杆菌在减少龋齿和细菌引发龋齿中的用途
WO2012060312A1 (ja) * 2010-11-05 2012-05-10 国立大学法人広島大学 籾殻または玄米から単離された植物乳酸菌およびその利用
RU2515113C2 (ru) * 2008-06-11 2014-05-10 Басф Се Средство (варианты), композиция (варианты) и применение средства (варианты) для снижения неприятного запаха изо рта
EP2740482A4 (en) * 2011-08-05 2015-03-04 Yakult Honsha Kk PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OF THE MOUTH VALVE
RU2584610C2 (ru) * 2010-08-18 2016-05-20 Аб-Биотикс С.А. Пробиотическая композиция для здоровья полости рта
CN113005055A (zh) * 2021-02-08 2021-06-22 无限极(中国)有限公司 预防和/或治疗牙周炎的植物乳杆菌、其培养物及其制备和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003250493A (ja) * 2001-12-28 2003-09-09 Toyo Shinyaku:Kk 麦若葉造粒物からなる虫歯予防食品
WO2003082027A1 (fr) * 2002-03-29 2003-10-09 Frente International Co., Ltd. Preparations cellulaires vitales et aliments contenant une bacterie lactique comme principe actif
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
KR100845034B1 (ko) * 2006-08-31 2008-07-08 경북대학교 산학협력단 충치균 성장을 억제하는 항균제를 생성하는 락토바실루스파라플란타룸 knuc25로부터 제조된 충치균 항균제
MX343566B (es) * 2010-08-31 2016-11-09 Centro Superior De Investig En Salud Publica (Csisp) * Composiciones y probioticos/prebioticos anticaries.
JP2014508136A (ja) * 2011-01-24 2014-04-03 ビーエーエスエフ ソシエタス・ヨーロピア 口腔衛生を向上させる組成物
CN108795734A (zh) * 2018-03-16 2018-11-13 孙百莉 一种乳酸菌检测系统及其制作方法
KR102630612B1 (ko) * 2021-02-10 2024-01-31 숙명여자대학교산학협력단 신규한 엔테로코커스 패칼리스 균주 및 이의 유청 발효물을 포함하는 구강질환 또는 대장질환의 예방 또는 개선용 식품 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2727236A1 (de) * 1976-06-21 1977-12-22 Inst Rech Scient Irs Verfahren zur herstellung von loesungen filtrierter lysate, wobei von mikroorganismenkulturen ausgegangen wird und danach hergestelltes heilmittel
US4746512A (en) * 1984-03-09 1988-05-24 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Anticariogenic or antiperiodontitic agent
EP0524732A2 (en) * 1991-06-28 1993-01-27 Aizo Matsushiro Composition containing lactic acid bacteria for preventing dental caries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2727236A1 (de) * 1976-06-21 1977-12-22 Inst Rech Scient Irs Verfahren zur herstellung von loesungen filtrierter lysate, wobei von mikroorganismenkulturen ausgegangen wird und danach hergestelltes heilmittel
US4746512A (en) * 1984-03-09 1988-05-24 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Anticariogenic or antiperiodontitic agent
EP0524732A2 (en) * 1991-06-28 1993-01-27 Aizo Matsushiro Composition containing lactic acid bacteria for preventing dental caries

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173555A1 (en) * 1999-04-26 2002-01-23 Innoscent Ltd. Method and kit for indicating the level of bad breath
EP1173555A4 (en) * 1999-04-26 2002-07-10 Innoscent Ltd METHOD AND KIT FOR DISPLAYING THE DEGREE OF SMELLING BREATH
JP2003502375A (ja) * 1999-06-21 2003-01-21 ブイエスエル・ファーマ・リミテッド 乳酸菌の配合物並びに感染症および炎症の予防および/または処置のためのその使用
JP2015043775A (ja) * 1999-06-21 2015-03-12 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ 乳酸菌の配合物並びに感染症および炎症の予防および/または処置のためのその使用
JP2012110334A (ja) * 1999-06-21 2012-06-14 Actial Farmaceutica Soc Por Quotas De Responsabilidade Ltda 乳酸菌の配合物並びに感染症および炎症の予防および/または処置のためのその使用
JP4949580B2 (ja) * 1999-06-21 2012-06-13 アクティアル・ファルマセウティカ・ソシエダデ・ポル・クオタス・デ・レスポンサビリダデ・リミターダ 乳酸菌の配合物並びに感染症および炎症の予防および/または処置のためのその使用
WO2002080946A1 (en) * 2001-04-02 2002-10-17 Wakamoto Pharmaceutical Co.,Ltd. Compositions for preventing and/or treating oral diseases
US8168072B2 (en) 2001-08-06 2012-05-01 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
WO2003014029A3 (en) * 2001-08-06 2004-03-18 A Y Lab Ltd Control of development of biofilms in industrial process water
US7927496B2 (en) 2001-08-06 2011-04-19 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
US7628929B2 (en) 2001-08-06 2009-12-08 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
US8444858B2 (en) 2001-08-06 2013-05-21 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
US7189329B2 (en) 2001-08-06 2007-03-13 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
US7052614B2 (en) 2001-08-06 2006-05-30 A.Y. Laboratories Ltd. Control of development of biofilms in industrial process water
CN102352324A (zh) * 2003-01-29 2012-02-15 生命大地女神有限公司 乳酸杆菌在减少龋齿和细菌引发龋齿中的用途
RU2515113C2 (ru) * 2008-06-11 2014-05-10 Басф Се Средство (варианты), композиция (варианты) и применение средства (варианты) для снижения неприятного запаха изо рта
RU2584610C2 (ru) * 2010-08-18 2016-05-20 Аб-Биотикс С.А. Пробиотическая композиция для здоровья полости рта
WO2012060312A1 (ja) * 2010-11-05 2012-05-10 国立大学法人広島大学 籾殻または玄米から単離された植物乳酸菌およびその利用
EP2740482A4 (en) * 2011-08-05 2015-03-04 Yakult Honsha Kk PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OF THE MOUTH VALVE
AU2012293231B2 (en) * 2011-08-05 2017-04-13 Kabushiki Kaisha Yakult Honsha Prophylactic or therapeutic agent for oral diseases
US9730883B2 (en) 2011-08-05 2017-08-15 Kabushiki Kaisha Yakult Honsha Prophylactic or therapeutic agent for oral diseases
CN113005055A (zh) * 2021-02-08 2021-06-22 无限极(中国)有限公司 预防和/或治疗牙周炎的植物乳杆菌、其培养物及其制备和应用
CN113005055B (zh) * 2021-02-08 2022-06-17 无限极(中国)有限公司 预防和/或治疗牙周炎的植物乳杆菌、其培养物及其制备和应用

Also Published As

Publication number Publication date
AU752706B2 (en) 2002-09-26
KR100266752B1 (ko) 2001-03-02
CN1268172A (zh) 2000-09-27
EP1002052A1 (en) 2000-05-24
KR19990023039A (ko) 1999-03-25
JP2001512670A (ja) 2001-08-28
IL134410A0 (en) 2001-04-30
MXPA00001347A (es) 2002-03-01
CA2299627A1 (en) 1999-02-18
TR200000360T2 (tr) 2000-07-21
BR9814737A (pt) 2000-10-03
AU8131298A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
AU752706B2 (en) Novel lactic acid bacteria
US20050129629A1 (en) Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US20050238590A1 (en) Incorporation of exogenous lactic bacteria into the oral microflora
US6036952A (en) Lactic acid bacteria inhibiting the formation of dental plaque in the mouth
KR100605992B1 (ko) 구취를 억제하는 유산균
JP4846643B2 (ja) 新規乳酸菌
JP2006508943A (ja) 酵母成長を阻害するための方法
US7491386B2 (en) Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains
US20030077814A1 (en) Novel lactic acid bacteria
JP4982636B2 (ja) 虫歯予防用組成物
KR900001433B1 (ko) 충치억제용 조성물 및 음료의 제조방법
JPS59220191A (ja) 非う蝕性組成物および飲料
KR19990086509A (ko) 인체 구강내 혐기성 세균을 억제하는 유산균
KR20060043665A (ko) 구취를 억제하는 유산균
JPH03251171A (ja) 非う蝕性微生物の製法及び非う蝕性組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134410

Country of ref document: IL

Ref document number: 98807912.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN IL JP MX TR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2299627

Country of ref document: CA

Ref document number: 2299627

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 81312/98

Country of ref document: AU

Ref document number: PA/a/2000/001347

Country of ref document: MX

Ref document number: 2000/00360

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1998931104

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998931104

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 81312/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998931104

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI9814737

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE AO ARQUIVAMENTO DA PETICAO DE ENTRADA NA FASE NACIONAL